BioSpace News Archive

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for CAUMZ™ following the previously announced Type B meeting with the US Food and Drug Administration.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2019, and provided full-year 2020 financial guidance.

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that management will present at the Cowen 40th Annual Health Care Conference in Boston, Massachusetts on Wednesday, March 4, 2020 at 10:00am Eastern Time.

10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 40th Annual Cowen Health Care Conference in Boston, MA.

Fixed-dose combination is administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment

Lysogene announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its LYS-SAF302 program for the treatment of mucopolysaccharidosis Type IIIA.

LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesday, March 3, 2020. The time has been revised to 12:00 noon Greenwich Mean Time (GMT) / 7:00 am Eastern Standard Time (EST) / 8:00 pm Hong Kong Time (HKT). Due to travel restrictions resulting from the novel coronavirus outbreak, Chi-Med managem

Hansa Biopharma has been invited to participate in two global biotech and healthcare conferences during March including Cowen Annual Health Care Conference in Boston and Carnegie Nordic Healthcare Seminar in Stockholm

HELSINKI , Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson’s disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all patients will receive CDNF for an additional six months, are expected in Q3 2020. H

Feb. 25, 2020 08:05 UTC First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved durable clinical benefit lasting ≥ 6 months; including four partial regressions so far, overall response rate not yet reached as six patients remain on treatment Treatment well-tolerated with limited side effects observed IMV t